A successful example is the application of the fully humanized anti-RANKL mAb, Denosumab in clinical therapies of osteoporosis and bone loss caused by metastatic prostate or breast tumor, where the antibody acted as an inhibitor of RANKL-RANK pathway. The gene discussed is TNFSF11; the disease is osteoporosis.